Bcl-XL Proteolysis Targeting Chimera DT2216 Clinical Trials

0 actively recruiting trials

No change since July 2026

Also known as: APTaD DT2216, Antiapoptotic Protein Targeted Degrader DT2216, BCL-XL-specific PROTAC DT2216, Bcl-XL Degrader DT2216, Bcl-XL PROTAC DT2216 +6 more

No trials match the selected filters.

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.